PatientsVille.com Logo

PatientsVille

Antihemophilic Side Effects

Common Antihemophilic Side Effects


The most commonly reported Antihemophilic side effects (click to view or check a box to report):

Factor Viii Inhibition (18)
Haemorrhage (7)
Anti Factor Viii Antibody Positive (6)
Death (4)
Nausea (3)
Haematemesis (2)
Caesarean Section (2)
Maternal Exposure During Pregnancy (2)
No Adverse Event (2)
Hypersensitivity (2)
Haematoma (2)
White Blood Cell Count Decreased (2)
Therapeutic Response Decreased (2)
Shock (2)
Platelet Count Decreased (2)
Vertigo (2)
Von Willebrand's Disease (2)
Pulmonary Oedema (2)
Peripheral Vascular Disorder (1)
Portal Vein Thrombosis (1)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Antihemophilic Side Effects Reported to FDA

The following Antihemophilic reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Antihemophilic on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Anti Factor Viii Antibody Positive, Haematemesis, Shock Haemorrhagic, Hepatic Failure
This is a report of a 56-year-old male patient (weight: NA) from JP, suffering from the following symptoms/conditions: factor viii deficiency, who was treated with Antihemophilic Factor Viii (recombinant), Sucrose Formulated (dosage: 8000 U, Bolus, start time: NS), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
  • Anti Factor Viii Antibody Positive
  • Haematemesis
  • Shock Haemorrhagic
  • Hepatic Failure
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Antihemophilic Factor Viii (recombinant), Sucrose Formulated treatment in male patients, resulting in anti factor viii antibody positive side effect. The patient was hospitalized.

Anti Factor Viii Antibody Positive
This report suggests a potential Antihemophilic Factor Viii (recombinant), Sucrose Formulated Anti Factor Viii Antibody Positive side effect(s) that can have serious consequences. A 15-year-old male patient (weight: NA) from US was diagnosed with the following symptoms/conditions: immune tolerance induction,factor viii deficiency and used Antihemophilic Factor Viii (recombinant), Sucrose Formulated (dosage: 100 Iu/kg, Qd) starting NS. Soon after starting Antihemophilic Factor Viii (recombinant), Sucrose Formulated the patient began experiencing various side effects, including:
  • Anti Factor Viii Antibody Positive
Drugs used concurrently: NA. Although Antihemophilic Factor Viii (recombinant), Sucrose Formulated demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as anti factor viii antibody positive, may still occur.

Hypersensitivity, Feeling Abnormal, Product Quality Issue
This Hypersensitivity, Feeling Abnormal, Product Quality Issue problem was reported by a consumer or non-health professional from US. A 32-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On Aug 03, 2013 this consumer started treatment with Antihemophilic Factor (dosage: 12,000 Ius Once Daily Into A Vein). The following drugs were being taken at the same time: NA. When commencing Antihemophilic Factor, the patient experienced the following unwanted symptoms/side effects:
  • Hypersensitivity
  • Feeling Abnormal
  • Product Quality Issue
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as hypersensitivity, may become evident only after a product is in use by the general population.

No Therapeutic Response
This is a report of a 3-year-old male patient (weight: NA) from US. The patient developed the following symptoms/conditions: factor viii deficiency and was treated with Antihemophilic Factor, Human Recombinant (dosage: NA) starting NS. Concurrently used drugs: NA.Soon after that, the consumer experienced the following side effects:
  • No Therapeutic Response
This opens a possibility that Antihemophilic Factor, Human Recombinant treatment could cause the above reactions, including no therapeutic response, and some male subjects may be more susceptible.


Factor Viii Inhibition, Mass, Wound Secretion, Gastrointestinal Haemorrhage
A 20-year-old male patient (weight: NA) from DE with the following symptoms/conditions: hemophilia a,traumatic bleeding started Antihemophilic Factor Viii (recombinant), Sucrose Formulated treatment (dosage: NA) on NS. Soon after starting Antihemophilic Factor Viii (recombinant), Sucrose Formulated treatment, the subject experienced various side effects, including:
  • Factor Viii Inhibition
  • Mass
  • Wound Secretion
  • Gastrointestinal Haemorrhage
Concurrently used drugs: NA.The patient was hospitalized. This finding indicates that some male patients could be more vulnerable to Antihemophilic Factor Viii (recombinant), Sucrose Formulated.

Hypothermia, Pyrexia, Body Temperature Fluctuation
A 6-year-old male patient from GT (weight: NA) experienced symptoms, such as: NA and was treated with Antihemophilic Factor (recombinant), Sucrose Formulated Fs(dosage: Unk). The treatment was initiated on NS. After that a consumer reported the following side effect(s):
  • Hypothermia
  • Pyrexia
  • Body Temperature Fluctuation
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Antihemophilic Factor (recombinant), Sucrose Formulated Fs efficacy: NA.The patient was hospitalized.

Haemorrhage
In this report, Antihemophilic Factor (recombinant) was administered for the following condition: NA.A 0-year-old male consumer from KR (weight: NA) started Antihemophilic Factor (recombinant) treatment (dosage: Unk) on 201209.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Haemorrhage
A possible interaction with other drugs could have contributed to this reaction: NA.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Antihemophilic Factor (recombinant) treatment could be related to the listed above side effect(s).

Contusion
This is a report of the following Antihemophilic Factor (recombinant), Sucrose Formulated Fs side effect(s):
  • Contusion
A 11-year-old male patient from RU (weight: NA) presented with the following condition: prophylaxis,hemophilia a and received a treatment with Antihemophilic Factor (recombinant), Sucrose Formulated Fs (dosage: 500 Iu Twice A Week) starting: Dec 01, 2008.The following concurrently used drugs could have generated interactions: NA.The patient was hospitalized.This report suggests that a Antihemophilic Factor (recombinant), Sucrose Formulated Fs treatment could be associated with the listed above side effect(s).

Anti Factor Viii Antibody Positive, Muscle Haemorrhage
This Antihemophilic Factor Viii (recombinant), Sucrose Formulated report was submitted by a 60-year-old male consumer from DE (weight: NA). The patient was diagnosed with: colonoscopy,traumatic haematoma and Antihemophilic Factor Viii (recombinant), Sucrose Formulated was administered (dosage: 35 Iu/kg, Once) starting: 201103. The consumer developed a set of symptoms:
  • Anti Factor Viii Antibody Positive
  • Muscle Haemorrhage
Other drugs used simultaneously: NA.The patient was hospitalized.Those unexpected symptoms could be linked to a Antihemophilic Factor Viii (recombinant), Sucrose Formulated treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Haematoma
This is a report of a possible correlation between Antihemophilic Factor (recombinant), Sucrose Formulated Fs use and the following symptoms/side effect(s):
  • Haematoma
which could contribute to an assessment of Antihemophilic Factor (recombinant), Sucrose Formulated Fs risk profile.A male consumer from RU (weight: NA) was suffering from hemophilia a and was treated with Antihemophilic Factor (recombinant), Sucrose Formulated Fs (dosage: Unk) starting Mar 24, 2008.Other concurrent medications:
  • Haemoctin Sdh
The patient was hospitalized.

Anti Factor Viii Antibody Positive, Haemarthrosis
A 15-year-old male patient from COUNTRY NOT SPECIFIED (weight: NA) presented with the following symptoms: NA and after a treatment with Antihemophilic Factor Viii (recombinant), Sucrose Formulated (dosage: 50 Iu/kg, Bid) experienced the following side effect(s):
  • Anti Factor Viii Antibody Positive
  • Haemarthrosis
The treatment was started on NS. Antihemophilic Factor Viii (recombinant), Sucrose Formulated was used in combination with the following drugs:
  • Vancomycin
  • Amikacin
This report could alert potential Antihemophilic Factor Viii (recombinant), Sucrose Formulated consumers.

Cardiovascular Disorder, Nausea, Vertigo
In this report, a 17-year-old female patient from DE (weight: NA) was affected by a possible Antihemophilic Factor (human) Nos side effect.The patient was diagnosed with von willebrand^s disease. After a treatment with Antihemophilic Factor (human) Nos (dosage: 2000 Iu Prn Intravenous (not Otherwise Specified), start date: NS), the patient experienced the following side effect(s):
  • Cardiovascular Disorder
  • Nausea
  • Vertigo
The following simultaneously used drugs could have led to this reaction: NA.The patient was hospitalized.The findings here stress that side effects should be taken into consideration when evaluating a Antihemophilic Factor (human) Nos treatment.

Factor Viii Inhibition
This is a report of a male patient from TURKEY (weight: NA), who used Antihemophilic Factor (human) (dosage: 500 Iu, Weekly) for a treatment of factor viii deficiency. After starting a treatment on Sep 19, 2011, the patient experienced the following side effect(s):
  • Factor Viii Inhibition
The following drugs could possibly have interacted with the Antihemophilic Factor (human) treatment NA.Taken together, these observations suggest that a Antihemophilic Factor (human) treatment could be related to side effect(s), such as Factor Viii Inhibition.

Nausea, Vertigo, Peripheral Vascular Disorder
This nausea side effect was reported by a health professional from GERMANY. A 17-year-old female patient (weight:NA) experienced the following symptoms/conditions: von willebrand's disease. The patient was prescribed Antihemophilic Factor (human) (dosage: 2000 Iu Prn Intravenous (not Otherwise Specified)), which was started on NS. Concurrently used drugs: NA. When starting to take Antihemophilic Factor (human) the consumer reported the following symptoms:
  • Nausea
  • Vertigo
  • Peripheral Vascular Disorder
The patient was hospitalized. These side effects may potentially be related to Antihemophilic Factor (human).

Von Willebrand's Disease
This is a Antihemophilic Factor (human) side effect report of a female patient (weight:NA) from JAPAN, suffering from the following symptoms/conditions: NA, who was treated with Antihemophilic Factor (human) (dosage:NA, start time: NS), combined with: NA., and developed a serious reaction and a von willebrand's disease side effect. The patient presented with:
  • Von Willebrand's Disease
which developed after the beginning of treatment. This side effect report can indicate a possible existence of increased vulnerability to Antihemophilic Factor (human) treatment in female patients suffering from NA, resulting in von willebrand's disease.

Von Willebrand's Disease
This report suggests a potential Antihemophilic Factor (human) von willebrand's disease side effect(s) that can have serious consequences. A female patient from JAPAN (weight:NA) was diagnosed with the following health condition(s): NA and used Antihemophilic Factor (human) (dosage: NA) starting NS. Soon after starting Antihemophilic Factor (human) the patient began experiencing various side effects, including:
  • Von Willebrand's Disease
Drugs used concurrently:NA. Although Antihemophilic Factor (human) demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as von willebrand's disease, may still occur.

Caesarean Section, Maternal Exposure During Pregnancy
This caesarean section problem was reported by a physician from JAPAN. A 34-year-old female patient (weight: NA) was diagnosed with the following medical condition(s): NA.On NS a consumer started treatment with Antihemophilic Factor (human) (dosage: Unk). The following drugs/medications were being taken at the same time: NA. When commencing Antihemophilic Factor (human), the patient experienced the following unwanted symptoms /side effects:
  • Caesarean Section
  • Maternal Exposure During Pregnancy
Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as caesarean section, may become evident only after a product is in use by the general population.

Factor Viii Inhibition
This is a Antihemophilic Factor Nos side effect report of a male patient (weight: NA) from TURKEY. The patient developed the following symptoms/conditions: factor viii deficiency and was treated with Antihemophilic Factor Nos (dosage: 500 Unk, Unk) starting Jan 09, 2012. Concurrently used drugs: NA. Soon after that, the consumer experienced the following of symptoms:
  • Factor Viii Inhibition
This opens a possibility that Antihemophilic Factor Nos could cause factor viii inhibition and that some male patients may be more susceptible.


A 49-year-old male patient (weight: NA) from UNITED STATES with the following symptoms: NA started Antihemophilic Factor Nos treatment (dosage: NA) on NS. Soon after starting Antihemophilic Factor Nos treatment, the consumer experienced several side effects, including:
    . Concurrently used drugs: NA. This finding indicates that some patients can be more vulnerable to developing Antihemophilic Factor Nos side effects, such as death.

    Maternal Exposure During Pregnancy, Caesarean Section, No Adverse Event
    This maternal exposure during pregnancy side effect was reported by a physician from JAPAN. A 31-year-old female patient (weight:NA) experienced the following symptoms/conditions: factor viii deficiency,factor v deficiency.The patient was prescribed Antihemophilic Factor Viii (recombinant), Sucrose Formulated (dosage: NA), which was started on NS. Concurrently used drugs: NA..When starting to take Antihemophilic Factor Viii (recombinant), Sucrose Formulated the consumer reported symptoms, such as:
    • Maternal Exposure During Pregnancy
    • Caesarean Section
    • No Adverse Event
    These side effects may potentially be related to Antihemophilic Factor Viii (recombinant), Sucrose Formulated.

    Alanine Aminotransferase Increased, Anti Factor Viii Antibody Positive, Streptococcus Test Positive, Complement Factor C3 Decreased, Tachypnoea, Glomerulonephritis Rapidly Progressive, Lung Infiltration, Abdominal Distension
    This is a report of a 9-year-old male patient (weight: NA) from UNITED STATES, suffering from the following symptoms/conditions: NA, who was treated with Antihemophilic Factor (human) (dosage: 8 Iu/kg, Q1hr, During Hospital Admission, start time: NS), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
    • Alanine Aminotransferase Increased
    • Anti Factor Viii Antibody Positive
    • Streptococcus Test Positive
    • Complement Factor C3 Decreased
    • Tachypnoea
    • Glomerulonephritis Rapidly Progressive
    • Lung Infiltration
    • Abdominal Distension
    which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Antihemophilic Factor (human) treatment in male patients, resulting in alanine aminotransferase increased side effect.

    Factor Viii Inhibition
    This report suggests a potential Antihemophilic Factor (human) Factor Viii Inhibition side effect(s) that can have serious consequences. A male patient (weight: NA) from GERMANY was diagnosed with the following symptoms/conditions: NA and used Antihemophilic Factor (human) (dosage: 1250 Iu, 2x/day) starting Jul 16, 2010. Soon after starting Antihemophilic Factor (human) the patient began experiencing various side effects, including:
    • Factor Viii Inhibition
    Drugs used concurrently: NA.The patient was hospitalized. Although Antihemophilic Factor (human) demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as factor viii inhibition, may still occur.

    Renal Impairment
    This Renal Impairment problem was reported by a physician from JAPAN. A 42-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: factor viii deficiency. On NS this consumer started treatment with Antihemophilic Factor (human) (dosage: Daily Dose 2000 U). The following drugs were being taken at the same time:
    • Nafamostat (Unk)
    When commencing Antihemophilic Factor (human), the patient experienced the following unwanted symptoms/side effects:
    • Renal Impairment
    Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as renal impairment, may become evident only after a product is in use by the general population.

    Haemorrhagic Diathesis, Therapeutic Response Decreased
    This is a report of a 8-year-old male patient (weight: NA) from UNITED STATES. The patient developed the following symptoms/conditions: factor viii deficiency and was treated with Antihemophilic Factor (recombinant), Sucrose Formulated Fs (dosage: 40 Iu/kg, Qod) starting NS. Concurrently used drugs: NA.Soon after that, the consumer experienced the following side effects:
    • Haemorrhagic Diathesis
    • Therapeutic Response Decreased
    This opens a possibility that Antihemophilic Factor (recombinant), Sucrose Formulated Fs treatment could cause the above reactions, including haemorrhagic diathesis, and some male subjects may be more susceptible.

    Haemorrhage, Therapeutic Response Decreased
    A 6-year-old male patient (weight: NA) from UNITED STATES with the following symptoms/conditions: factor viii deficiency started Antihemophilic Factor (recombinant), Sucrose Formulated Fs treatment (dosage: 50 Iu/kg, Qod) on NS. Soon after starting Antihemophilic Factor (recombinant), Sucrose Formulated Fs treatment, the subject experienced various side effects, including:
    • Haemorrhage
    • Therapeutic Response Decreased
    Concurrently used drugs: NA. This finding indicates that some male patients could be more vulnerable to Antihemophilic Factor (recombinant), Sucrose Formulated Fs.

    1 of 3 



    Keep Track of Side Effects

    Note Your Observations

    It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

    Why Your Notes are Important

    Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Antihemophilic Side Effects

    Did You Have a Antihemophilic Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Antihemophilic for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Antihemophilic Safety Alerts, Active Ingredients, Usage Information

    More About Antihemophilic

    Side Effects reported to FDA: 51

    Antihemophilic safety alerts: 2000

    Reported deaths: 5

    Reported hospitalizations: 4

    Helixate (antihemophilic factor [recombinant])

    Voluntary withdrawal of Helixate lot number 670H071E. This lot of Helixate was tested for Factor VIII potency using a reagent known as FVIII-deficient plasma. During a routine quality assurance investigation of the testing procedure, Bayer learned that Lot 670H071 may not retain its labeled potency if held at room temperature (25° C) for 3 months. The product will remain stable if stored at 2-8° C. Further investigation has confirmed that the cause is not related to a stability issue with the product but is attributed to the reagent used during the initial testing. As of this date there have been no adverse events reported in association with this lot of Helixate.

    [August 1, 2000 - Letter - Aventis Behring]

    Latest Antihemophilic clinical trials

    Antihemophilic Reviews

    No reviews, be a first to report a side effect via side effect reporting form